Lung cancer clue: could a DNA glitch guide future treatments?
NCT ID NCT07303218
First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study examines whether a specific DNA repair problem, called homologous recombination deficiency (HRD), is common in a certain type of advanced lung cancer (EGFR-mutated NSCLC). Researchers will analyze tumor samples from 100 patients to see if HRD is linked to how the cancer behaves or responds to treatment. The goal is to better understand this cancer subgroup and explore whether they might benefit from PARP inhibitor drugs in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dept. Medical Oncology
Milan, MI, 20132, Italy
Conditions
Explore the condition pages connected to this study.